<DOC>
	<DOCNO>NCT00706355</DOCNO>
	<brief_summary>PF-04217903 may work cancer block cell growth , migration invasion tumor cell . PF-04217903 new member class drug call c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitor . This research study first time PF-04217903 give patient . PF-04217903 take mouth daily .</brief_summary>
	<brief_title>A Study PF-04217903 Patients With Advanced Cancer</brief_title>
	<detailed_description>The study prematurely discontinue due strategic development decision Pfizer 10FEB2012 . The decision terminate base safety concern .</detailed_description>
	<criteria>Advanced solid tumor , histologically proven diagnosis refractory standard care standard care therapy available Adequate blood cell count , normal kidney function , performance status 0 1 Major surgery , radiation therapy anticancer therapy within 2 week start study treatment Prior stem cell transplant Active unstable cardiac disease heart attack within 12 month start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>